🏛️ Verified NIH Record • Updated 2025-05-14
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL (NCT05555862)
A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Suppositories for the Treatment of HIV-negative Patients With Anal High-grade Squamous Intraepithelial Lesions (Anal HSIL)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Frantz Viral Therapeutics, LLC
🩺 Plain-English Summary (8th-Grade Level)
This is a phase II double blind, placebo-controlled, randomized study of Artesunate suppositories for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
Who can join: Review the eligibility criteria below.
Location: Anal Dysplasia Clinic MidWest — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Anal Dysplasia Clinic MidWest — Chicago, Illinois
- Laser Surgery Care — New York, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Anal High Grade Squamous Intraepithelial Lesion
- Safety of Anal Curcumin — Atlanta, Georgia
Explore by condition: All Anal High Grade Squamous Intraepithelial Lesion clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.